Accuracy of PCA3 Measurement in Predicting Short-Term Biopsy Progression in an Active Surveillance Program

Journal of Urology

Volumn 183, Issue 2, 2010, Pages 534-538

  Tosoian, Jeffrey J ^a   Loeb, Stacy ^a   Kettermann, Anna ^a   Landis, Patricia ^a   Elliot, Debra J ^a   Epstein, Jonathan I ^a   Partin, Alan W ^a   Carter, H Ballentine ^a   Sokoll, Lori J ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

biopsy; human; prostate cancer antigen 3; prostatic neoplasms

Indexed keywords

PROSTATE CANCER ANTIGEN 3; PROSTATE SPECIFIC ANTIGEN; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER GROWTH; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIGITAL RECTAL EXAMINATION; HEALTH PROGRAM; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; URINALYSIS;

AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; BIOPSY; DISEASE PROGRESSION; HUMANS; MALE; MIDDLE AGED; POPULATION SURVEILLANCE; PREDICTIVE VALUE OF TESTS; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS; TIME FACTORS;

EID: 73749086977     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2009.10.003     Document Type: Article

References (21)

1. American Cancer Society. Cancer Facts and Figures 2008. http://www.cancer.org/downloads/STT/2008CAFFfinalsecured.pdf Accessed March 5, 2008
2. Walsh P.C., Partin A.W., and Epstein J.I. Cancer control and quality of life following anatomical radical retropubic prostatectomy: results at 10 years. J Urol 152 (1994) 1831
3. Draisma G., Boer R., Otto S.J., et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 95 (2003) 868
4. Bill-Axelson A., Holmberg L., Filen F., et al. Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. J Natl Cancer Inst 100 (2008) 1144
5. Loeb S., Roehl K.A., Helfand B.T., et al. Complications of open radical retropubic prostatectomy in potential candidates for active monitoring. Urology 72 (2008) 887
6. Miller D.C., Gruber S.B., Hollenbeck B.K., et al. Incidence of initial local therapy among men with lower-risk prostate cancer in the United States. J Natl Cancer Inst 98 (2006) 1134
7. Bussemakers M.J., van Bokhoven A., Verhaegh G.W., et al. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res 59 (1999) 5975
8. Hessels D., Klein Gunnewiek J.M., van Oort I., et al. DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 44 (2003) 8
9. Whitman E.J., Groskopf J., Ali A., et al. PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume. J Urol 180 (2008) 1975
10. Nakanishi H., Groskopf J., Fritsche H.A., et al. PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance. J Urol 179 (2008) 1804
11. Carter H.B., Walsh P.C., Landis P., et al. Expectant management of nonpalpable prostate cancer with curative intent: preliminary results. J Urol 167 (2002) 1231
12. Carter H.B., Kettermann A., Warlick C., et al. Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience. J Urol 178 (2007) 2359
13. Epstein J.I., Walsh P.C., Carmichael M., et al. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 271 (1994) 368
14. Groskopf J., Aubin S.M., Deras I.L., et al. APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. Clin Chem 52 (2006) 1089
15. Sokoll L.J., Ellis W., Lange P., et al. A multicenter evaluation of the PCA3 molecular urine test: pre-analytical effects, analytical performance, and diagnostic accuracy. Clin Chim Acta 389 (2008) 1
16. Al Otaibi M., Ross P., Fahmy N., et al. Role of repeated biopsy of the prostate in predicting disease progression in patients with prostate cancer on active surveillance. Cancer 113 (2008) 286
17. Dall'Era M.A., Konety B.R., Cowan J.E., et al. Active surveillance for the management of prostate cancer in a contemporary cohort. Cancer 112 (2008) 2664
18. Stav K., Judith S., Merald H., et al. Does prostate biopsy Gleason score accurately express the biologic features of prostate cancer?. Urol Oncol 25 (2007) 383
19. Marks L.S., Fradet Y., Deras I.L., et al. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Urology 69 (2007) 532
20. Haese A., de la Taille A., van Poppel H., et al. Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol 54 (2008) 1081
21. Deras I.L., Aubin S.M., Blase A., et al. PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol 179 (2008) 1587